Jg. Garweg, Posterior segment involvement in HIV-associated eye disease after the commencement of highly active antiretroviral therapy (HAART), KLIN MONATS, 216(2), 2000, pp. 68-74
The panel of therapeutic options available for the treatment of retroviral
disorders has expanded explosively in recent years, with the result that it
has now became possible to reconstitute the immune function of individuals
with advanced HIV-disease to a remarkable degree. The ophthalmologist is t
hus confrontated with completely new clinical situations, courses of treatm
ent and decisions. For example, a CMV-retinitis developing within six weeks
of the onset of HAART does not necessarily require specific treatment, and
reactivation of a retinitis within the same time span is often barely dist
inguishable from an inflammatory reaction induced by the reconstituted lymp
hocytes. Marked cellular infiltration of the vitreous - in the absence of a
n active retinal or chorioretinal lesion - is the hallmark of this immune-r
ecovery vitreitis and responds nicely to systemic steroid treatment. In the
course of retinitis, macular edema and epiretinal membrane formation are n
ot uncommonly responsible for visual impairment. If, on the other hand, imm
unological parameters remain stable during the course of three months, i.e.
, if the CD4 cell count is more than 150-250 mu l and the plasma load of HI
V-T is less than 5-10,000 copies/mu l, then what has until now been deemed
to be a lifelong therapy for CMV-retinitis may be interrupted, provided the
clinical (i.e., retinal) situation can be controlled on a regular basis.
In this article, an attempt is made to discuss and interpret clinical findi
ngs pertaining to posterior segment involvement in ocular HIV disease, with
a view to guiding the clinical practitioner in his/her course of action.